UnitedHealth Group Inc. (NYSE:UNH)

The provision for income taxes exhibited fluctuating behavior over the five-year period. While generally positive, representing an expense, the composition between current and deferred components shifted considerably. A review of the individual elements reveals distinct trends.

Current Provision

The current provision demonstrated an initial increase from US$4,448 million in 2021 to US$6,377 million in 2022. Following this peak, the current provision experienced a slight decrease to US$6,213 million in 2023, then a more substantial decline to US$5,125 million in 2024. This downward trend continued into 2025, with the current provision falling to US$3,642 million. This suggests a decreasing tax liability related to current taxable income.

Deferred Benefit (Expense)

The deferred component initially represented a modest benefit of US$130 million in 2021. However, it transitioned to a significant benefit in 2022, becoming a substantial expense of US$673 million. This expense continued, though at a reduced level, in 2023 (US$245 million) and 2024 (US$296 million). The deferred component then became a considerably larger expense in 2025, reaching US$1,752 million. This indicates increasing deferred tax liabilities, potentially due to changes in temporary differences between book and tax accounting.

Total Provision for Income Taxes

The total provision for income taxes mirrored the combined effect of the current provision and deferred benefit. It rose from US$4,578 million in 2021 to US$5,704 million in 2022, peaked at US$5,968 million in 2023, and then decreased to US$4,829 million in 2024. A significant reduction occurred in 2025, with the total provision falling to US$1,890 million. The substantial decrease in the total provision in 2025 is largely attributable to the increased deferred tax expense offsetting the decline in the current provision.

The interplay between the current provision and deferred benefit suggests evolving tax positions and potentially changes in the recognition of future tax consequences. The increasing deferred tax expense warrants further investigation to understand the underlying temporary differences driving this trend.

The effective income tax rate exhibited fluctuations over the five-year period. While the U.S. federal statutory tax rate remained constant at 21.00%, the effective income tax rate demonstrated considerable variability.

Effective Income Tax Rate Trend

In 2021, the effective income tax rate was 20.50%, slightly below the statutory rate. This increased to 21.70% in 2022, exceeding the statutory rate. The rate then decreased to 20.50% in 2023, returning to the level observed in 2021. A significant increase was noted in 2024, with the effective income tax rate rising to 24.10%. Subsequently, a substantial decline occurred in 2025, with the rate falling to 12.90%.

The variations in the effective income tax rate suggest the presence of factors influencing the company’s tax obligations beyond the standard corporate tax rate. These factors could include tax credits, deductions, changes in the mix of income sources (e.g., geographic distribution or types of income), or adjustments related to deferred tax assets and liabilities. The considerable decrease in 2025 warrants further investigation to determine the underlying causes, such as a one-time benefit or a shift in the company’s financial structure.

Deviation from Statutory Rate

The effective income tax rate deviated from the statutory rate in each year. The largest positive deviation occurred in 2024, indicating a higher tax burden relative to the statutory rate. Conversely, the most significant negative deviation was observed in 2025, suggesting a lower tax burden. These deviations highlight the importance of considering factors beyond the statutory rate when assessing the company’s tax position.

The observed trends indicate that the company’s tax strategy and financial performance have a material impact on its effective income tax rate. Continued monitoring of this rate, alongside the underlying factors driving its fluctuations, is recommended.

The composition of deferred tax assets and liabilities exhibits notable shifts over the five-year period. Overall, the net deferred income tax position transitions from a net liability to a smaller net liability. Significant changes are observed in both the components of deferred tax assets and deferred tax liabilities.

Deferred Tax Assets

Deferred tax assets, before valuation allowances, generally increased from 2021 to 2023, peaking at US$5,061 million, before declining in 2024 and 2025. The increase was driven by several factors, including growth in accrued expenses and allowances, U.S. federal and state net operating loss carryforwards, share-based compensation, and other domestic and non-U.S. items. A substantial increase in net unrealized losses on investments contributed to the asset base in 2022 and 2023. Valuation allowances consistently increased throughout the period, offsetting a portion of the gross deferred tax assets. The growth in valuation allowances suggests increasing uncertainty regarding the realization of certain deferred tax assets.

Key Deferred Tax Asset Components

Accrued expenses and allowances demonstrate a consistent upward trend, increasing from US$723 million in 2021 to US$1,282 million in 2025. U.S. federal and state net operating loss carryforwards fluctuated, peaking in 2022 at US$540 million before decreasing, and then increasing again to US$566 million in 2025. Share-based compensation also increased steadily over the period. Other, non-U.S. items experienced a significant increase from US$811 million in 2021 to US$1,545 million in 2023, followed by a substantial decrease to US$275 million in 2025.

Deferred Tax Liabilities

Deferred tax liabilities decreased consistently from US$6,813 million in 2021 to US$6,528 million in 2025. This decrease is attributable to reductions in several liability components. The largest component, U.S. federal and state intangible assets, decreased steadily throughout the period. Capitalized software and outside basis in partnerships also experienced consistent declines. A significant decrease is observed in other, non-U.S. items, particularly from 2023 to 2025.

Key Deferred Tax Liability Components

U.S. federal and state intangible assets represent the largest deferred tax liability, decreasing from US$2,658 million in 2021 to US$4,347 million in 2025. Capitalized software decreased from US$833 million to US$152 million over the same period. Lease right-of-use assets also decreased, though at a slower rate, from US$1,267 million to US$800 million. The reduction in these components likely reflects the amortization of related assets and the recognition of associated tax benefits.

Net Deferred Income Tax Position

The net deferred income tax position, representing the difference between deferred tax liabilities and deferred tax assets, improved from a net liability of US$3,265 million in 2021 to a net liability of US$2,421 million in 2025. This improvement is driven by the combined effect of decreasing deferred tax liabilities and increasing deferred tax assets, although the growth in valuation allowances partially offsets the asset increases.

The deferred income tax liabilities exhibited fluctuations over the five-year period. An initial decrease was followed by periods of increase and decrease, concluding with a value below the starting point.

Overall Trend

The deferred income tax liabilities began at US$3,265 million in 2021, decreased to US$2,769 million in 2022, and then increased to US$3,021 million in 2023. A further increase to US$3,620 million occurred in 2024, before declining to US$2,421 million in 2025. This represents a net decrease over the period.

Year-over-Year Changes

The largest year-over-year decrease was observed between 2021 and 2022, with a reduction of US$496 million. The most substantial increase occurred between 2023 and 2024, amounting to US$600 million. The final year, 2024 to 2025, saw a decrease of US$1,199 million, the largest single-year decline in the observed period.

Potential Implications

The volatility in deferred tax liabilities could indicate changes in temporary differences between the book and tax bases of assets and liabilities. The decrease in 2025 may suggest a realization of previously recorded deferred tax liabilities, or changes in applicable tax laws or rates. Further investigation into the underlying causes of these fluctuations would be necessary to fully understand their impact.

The information presents a five-year trend of reported and adjusted financial statement items. The adjustments consistently relate to the removal of deferred tax liabilities, impacting total liabilities and shareholders’ equity, with a corresponding, though smaller, effect on net earnings. A general pattern of increasing reported values from 2021 to 2023 is observed across all items, followed by declines in 2024 and 2025.

Total Liabilities

Reported total liabilities increased from US$135,727 million in 2021 to US$174,801 million in 2023, representing a substantial rise. This was followed by a decrease to US$195,687 million in 2024 and further to US$207,883 million in 2025. The adjusted total liabilities follow a similar trajectory, consistently lower than the reported figures, indicating the impact of deferred tax liability adjustments. The difference between reported and adjusted liabilities narrowed in 2025.

Shareholders’ Equity

Reported shareholders’ equity attributable to UnitedHealth Group exhibited growth from US$71,760 million in 2021 to US$88,756 million in 2023. Similar to liabilities, a decline is noted in 2024 (US$92,658 million) and 2025 (US$94,110 million). Adjusted shareholders’ equity consistently exceeds reported equity, reflecting the removal of deferred tax liabilities. The increase in adjusted equity is more pronounced than the increase in reported equity, suggesting a significant impact from the adjustments.

Net Earnings

Reported net earnings attributable to UnitedHealth Group common shareholders increased from US$17,285 million in 2021 to US$22,381 million in 2023, then decreased significantly to US$14,405 million in 2024 and US$12,056 million in 2025. Adjusted net earnings mirror this trend, with the adjustments resulting in slightly higher earnings in 2021, 2022, and 2023, and slightly lower earnings in 2024 and 2025. The magnitude of the adjustment to net earnings is relatively small compared to the adjustments made to liabilities and equity.

The consistent removal of deferred tax liabilities appears to be a key factor influencing the differences between reported and adjusted figures. The declines observed in 2024 and 2025 across all items suggest a potential shift in financial performance or accounting practices. Further investigation would be required to determine the underlying causes of these changes.

The financial metrics demonstrate a consistent pattern between reported and adjusted values across the observed period. Adjustments, primarily related to the removal of deferred tax impacts, generally result in slight modifications to the reported figures, though the directional trends remain largely consistent. However, the magnitude of the difference between reported and adjusted values appears to increase in later years, particularly from 2024 onwards.

Profitability Ratios

Reported net profit margin initially increased from 6.06% in 2021 to 6.25% in 2022, before declining significantly to 3.65% in 2024 and further to 2.72% in 2025. The adjusted net profit margin mirrors this trend, though the absolute values are slightly different. The adjustments consistently result in a marginally higher net profit margin in 2021 and 2022, but a slightly lower margin in 2024 and 2025. This suggests that deferred tax assets or liabilities are having a more pronounced negative impact on reported earnings in the later periods.

Leverage Ratio

Reported financial leverage exhibits a gradual increase from 2.96 in 2021 to 3.29 in 2025. The adjusted financial leverage also shows an increasing trend, but remains consistently lower than the reported value across all years. The difference between the reported and adjusted leverage is relatively small in the earlier years, but widens slightly in 2024 and 2025. This indicates that deferred tax items contribute to a higher reported leverage compared to the adjusted view.

Return on Equity (ROE)

Reported ROE peaked at 25.87% in 2022, then experienced a substantial decline to 15.55% in 2024 and 12.81% in 2025. The adjusted ROE follows a similar trajectory, though the absolute values are lower. The adjustments consistently reduce the reported ROE, with the largest difference observed in 2024 and 2025, reinforcing the observation that deferred taxes are increasingly impacting reported equity returns.

Return on Assets (ROA)

Reported ROA remained relatively stable around 8.15% - 8.19% from 2021 to 2023, before decreasing to 4.83% in 2024 and 3.89% in 2025. The adjusted ROA shows a slightly different pattern, with a decrease in 2022, but generally tracking the reported ROA. The adjustments lead to a slightly higher ROA in 2021 and 2023, but a lower ROA in 2024 and 2025. This suggests a growing influence of deferred tax items on asset returns in the later periods.

In summary, the adjustments related to deferred taxes have a consistent, though generally small, impact on the reported financial ratios. However, the magnitude of this impact appears to be increasing from 2024 onwards, particularly affecting profitability and return metrics. This trend warrants further investigation to understand the underlying drivers of the deferred tax changes and their implications for the company’s financial performance.

The reported and adjusted net earnings attributable to UnitedHealth Group common shareholders demonstrate fluctuations over the five-year period. While both metrics generally increased from 2021 to 2023, a noticeable decline is observed in 2024 and 2025. The adjusted net earnings consistently remain slightly above the reported net earnings each year, suggesting the impact of certain adjustments to reported figures.

Reported Net Profit Margin

The reported net profit margin exhibited an initial increase from 6.06% in 2021 to 6.25% in 2022. It then decreased slightly to 6.09% in 2023 before experiencing a substantial decline to 3.65% in 2024 and further to 2.72% in 2025. This indicates a diminishing profitability based on reported earnings.

Adjusted Net Profit Margin

The adjusted net profit margin followed a similar pattern to the reported net profit margin. It began at 6.10% in 2021, decreased to 6.04% in 2022, remained relatively stable at 6.02% in 2023, and then declined significantly to 3.57% in 2024 and 2.32% in 2025. The consistent decrease in the adjusted net profit margin over the latter two years suggests underlying pressures on profitability even after accounting for adjustments.

The convergence of the reported and adjusted net profit margins in 2024 and 2025 suggests that the adjustments made to net earnings have a lessening impact on the overall profitability picture during those years. The pronounced downward trend in both margins from 2023 to 2025 warrants further investigation to determine the contributing factors, such as changes in revenue, cost of goods sold, or operating expenses.

The difference between reported and adjusted net earnings remains relatively small throughout the period, indicating that the adjustments are not materially altering the overall earnings picture. However, the consistent presence of adjustments suggests that they represent recurring items that management deems relevant for assessing underlying business performance.

Analysis reveals a generally increasing trend in both reported and adjusted shareholders’ equity attributable to the group between 2021 and 2025. Reported shareholders’ equity grew from US$71,760 million to US$94,110 million, while adjusted shareholders’ equity increased from US$75,025 million to US$96,531 million over the same period. Both metrics demonstrate consistent, albeit decelerating, growth.

Reported Financial Leverage

Reported financial leverage exhibited a slight increasing trend overall, moving from 2.96 in 2021 to 3.29 in 2025. There was a moderate increase from 2021 to 2022, followed by a slight decrease in 2023, and then a continued increase through 2025. The fluctuations suggest a dynamic relationship between assets and reported equity.

Adjusted Financial Leverage

Adjusted financial leverage followed a similar pattern to reported financial leverage, beginning at 2.83 in 2021 and reaching 3.21 in 2025. The trend indicates a gradual increase in leverage when shareholders’ equity is adjusted. The adjusted leverage remained consistently below the reported leverage throughout the period, suggesting that the adjustments to equity reduce the calculated leverage ratio.

The difference between reported and adjusted financial leverage narrowed slightly from 0.13 in 2021 to 0.08 in 2025. This indicates that the impact of the equity adjustments on the leverage calculation is becoming less pronounced over time. The consistent increase in both leverage ratios, despite growing equity, suggests that asset growth has outpaced equity growth during the analyzed period.

The relatively stable and moderate increases in both reported and adjusted financial leverage suggest a controlled approach to financial risk. However, continued monitoring is warranted to ensure that leverage remains within acceptable parameters as the company continues to grow.

The period between 2021 and 2025 demonstrates fluctuating performance in reported and adjusted net earnings attributable to UnitedHealth Group common shareholders. While both reported and adjusted net earnings increased from 2021 to 2023, a significant decline is observed in 2024 and 2025. Shareholders’ equity, both reported and adjusted, generally increased over the five-year period, though the rate of increase slowed in the later years. Consequently, both reported and adjusted return on equity (ROE) exhibit a similar pattern of initial growth followed by a substantial decrease.

Net Earnings Trend

Reported net earnings increased from US$17,285 million in 2021 to US$22,381 million in 2023, representing a growth of approximately 29.5%. However, these earnings decreased significantly to US$14,405 million in 2024 and further to US$12,056 million in 2025. Adjusted net earnings follow a similar trajectory, increasing from US$17,415 million in 2021 to US$22,136 million in 2023, before declining to US$14,109 million in 2024 and US$10,304 million in 2025. The declines in both reported and adjusted net earnings between 2023 and 2025 are substantial, indicating a potential shift in profitability.

Shareholders’ Equity Trend

Reported shareholders’ equity increased from US$71,760 million in 2021 to US$92,658 million in 2024, and then to US$94,110 million in 2025. Adjusted shareholders’ equity shows a similar pattern, rising from US$75,025 million in 2021 to US$96,278 million in 2024, and US$96,531 million in 2025. The growth rate of shareholders’ equity appears to decelerate in 2024 and 2025, suggesting a possible stabilization or slower accumulation of equity.

Reported ROE Analysis

Reported ROE increased from 24.09% in 2021 to 25.87% in 2022, then decreased slightly to 25.22% in 2023. A significant decline is then observed, with ROE falling to 15.55% in 2024 and further to 12.81% in 2025. This decrease aligns with the decline in reported net earnings, indicating a reduced return generated on shareholders’ equity.

Adjusted ROE Analysis

Adjusted ROE mirrors the trend of reported ROE, increasing from 23.21% in 2021 to 24.15% in 2022, and remaining relatively stable at 24.12% in 2023. Similar to reported ROE, a substantial decrease is observed in 2024 (14.65%) and 2025 (10.67%). The adjusted ROE consistently remains slightly below the reported ROE throughout the period. The significant drop in adjusted ROE in the later years suggests a weakening in the company’s ability to generate profits from its equity base, even when considering adjustments to net earnings and shareholders’ equity.

The convergence of declining net earnings and a slowing growth rate in shareholders’ equity results in a pronounced decrease in both reported and adjusted ROE. Further investigation is warranted to understand the underlying factors contributing to the decline in profitability observed in 2024 and 2025.

Reported net earnings attributable to UnitedHealth Group common shareholders exhibited an increasing trend from 2021 to 2023, peaking at US$22,381 million, before declining significantly in both 2024 and 2025 to US$14,405 million and US$12,056 million, respectively. Adjusted net earnings followed a similar pattern, increasing through 2023 and then decreasing in the subsequent two years, though the decline was more pronounced in 2025, falling to US$10,304 million. The reported and adjusted Return on Assets (ROA) metrics generally mirrored this trend.

Reported ROA

Reported ROA remained relatively stable between 2021 and 2023, fluctuating between 8.15% and 8.19%. A substantial decrease is observed in 2024, with the reported ROA falling to 4.83%, and this downward trend continued into 2025, reaching 3.89%. This suggests a diminishing ability to generate earnings from its asset base.

Adjusted ROA

Adjusted ROA showed a slight decrease from 8.21% in 2021 to 7.91% in 2022, followed by a recovery to 8.09% in 2023. Similar to the reported ROA, a significant decline occurred in 2024, dropping to 4.73%, and continued in 2025 to 3.33%. The adjusted ROA consistently remained slightly below the reported ROA throughout the period.

Relationship between Net Earnings and ROA

The declines in both reported and adjusted ROA in 2024 and 2025 correlate with the decreases in reported and adjusted net earnings during the same period. This indicates that the reduction in profitability directly impacted the company’s efficiency in utilizing its assets to generate returns. The magnitude of the ROA decline appears proportional to the decline in net earnings.

Adjustments Impact

The difference between reported and adjusted ROA is minimal across all years, suggesting that the adjustments made to net earnings have a limited impact on the overall ROA calculation. However, the adjusted ROA consistently provides a slightly lower return figure, indicating that the adjustments generally reduce reported profitability.

In summary, the period demonstrates a shift from growth in earnings and asset utilization through 2023 to a period of declining performance in 2024 and 2025, as evidenced by the decreasing ROA metrics. The consistency between reported and adjusted figures suggests the underlying operational performance is the primary driver of these changes.